An update on HLA alleles associated with adverse drug reactions.
Adverse drug reactions (ADRs) are considered as an important cause of morbidity and mortality. The hypersensitivity reactions are immune-mediated ADRs, which are dose-independent, unpredictable and have been associated with several HLA alleles. The present review aimed to describe HLA alleles that have been associated with different ADRs in populations worldwide, the recommendations of regulatory agencies and pharmacoeconomic information and databases for the study of HLA alleles in pharmacogenetics. A systematic search was performed in June 2016 of articles relevant to this issue in indexed journals and in scientific databases (PubMed and PharmGKB). The information of 95 association studies found was summarized. Several HLA alleles and haplotypes have been associated with ADRs induced mainly by carbamazepine, allopurinol, abacavir and nevirapine, among other drugs. Years with the highest numbers of publications were 2013 and 2014. The majority of the reports have been performed on Asians and Caucasians, and carbamazepine was the most studied ADR drug inducer. Two HLA alleles' databases are described, as well as the recommendations of the U.S. Food and Drug Administration, the European Medicine Agency and the Clinical Pharmacogenetics Implementation Consortium. Pharmacoeconomic studies on this issue are also mentioned. The strongest associations remain for HLA-B*58:01, HLA-B*57:01, HLA-B*15:02 and HLA-A*31:01 but only in certain populations; therefore, studies on different ethnic groups would be useful. Due to the improvement of drug therapy and the economic benefit that HLA screening represents, investigations on HLA alleles associated with ADR should continue.
.
Ingrid
I
Fricke-Galindo
.
Adrián
A
LLerena
.
Marisol
M
López-López
D000483:Alleles; D000493:Allopurinol / Q000009:adverse effects*; D002220:Carbamazepine / Q000009:adverse effects*; D015224:Dideoxynucleosides / Q000009:adverse effects*; D064420:Drug-Related Side Effects and Adverse Reactions; D017850:Economics, Pharmaceutical; D006680:HLA Antigens / Q000235:genetics*; D006801:Humans; D019829:Nevirapine / Q000009:adverse effects*; D000099227:Abacavir
D000493:Allopurinol; D002220:Carbamazepine; D015224:Dideoxynucleosides; D006680:HLA Antigens; D019829:Nevirapine; D000099227:Abacavir
Stevens-Johnson syndrome; abacavir; adverse drug reactions; allopurinol; carbamazepine; human leukocyte antigen (HLA); hypersensitivity syndrome; pharmacogenetics